N S Minczeles1,2,3, J Hofland1,3, W W de Herder1,3, T Brabander4,5. 1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC and Erasmus MC Cancer Center, Rotterdam, The Netherlands. 2. Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. 3. ENETS Center of Excellence Rotterdam, Rotterdam, The Netherlands. 4. Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. t.brabander@erasmusmc.nl. 5. ENETS Center of Excellence Rotterdam, Rotterdam, The Netherlands. t.brabander@erasmusmc.nl.
Abstract
PURPOSE OF REVIEW: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on possible extensions of the current use of PRRT and on new approaches which could further improve its treatment efficacy and safety. RECENT FINDINGS: Promising results were published regarding PRRT in other NENs, including lung NENs or high-grade NENs, and applying PRRT as neoadjuvant or salvage therapy. Furthermore, a diversity of strategic approaches, including dosimetry, somatostatin receptor antagonists, somatostatin receptor upregulation, radiosensitization, different radionuclides, albumin binding, alternative renal protection, and liver-directed therapy in combination with PRRT, have the potential to improve the outcome of PRRT. Also, novel biomarkers are presented that could predict response to PRRT. Multiple preclinical and early clinical studies have shown encouraging potential to advance the clinical outcome of PRRT in NEN patients. However, at this moment, most of these strategies have not yet reached the clinical setting of randomized phase III trials.
PURPOSE OF REVIEW: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on possible extensions of the current use of PRRT and on new approaches which could further improve its treatment efficacy and safety. RECENT FINDINGS: Promising results were published regarding PRRT in other NENs, including lung NENs or high-grade NENs, and applying PRRT as neoadjuvant or salvage therapy. Furthermore, a diversity of strategic approaches, including dosimetry, somatostatin receptor antagonists, somatostatin receptor upregulation, radiosensitization, different radionuclides, albumin binding, alternative renal protection, and liver-directed therapy in combination with PRRT, have the potential to improve the outcome of PRRT. Also, novel biomarkers are presented that could predict response to PRRT. Multiple preclinical and early clinical studies have shown encouraging potential to advance the clinical outcome of PRRT in NEN patients. However, at this moment, most of these strategies have not yet reached the clinical setting of randomized phase III trials.
Authors: Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker Journal: J Nucl Med Date: 2010-08-18 Impact factor: 10.057
Authors: Esther I van Vliet; Casper H van Eijck; Ronald R de Krijger; Elisabeth J Nieveen van Dijkum; Jaap J Teunissen; Boen L Kam; Wouter W de Herder; Richard A Feelders; Bert A Bonsing; Tessa Brabander; Eric P Krenning; Dik J Kwekkeboom Journal: J Nucl Med Date: 2015-08-13 Impact factor: 10.057
Authors: Anna Yordanova; Marcel M Wicharz; Karin Mayer; Peter Brossart; Maria A Gonzalez-Carmona; Christian P Strassburg; Rolf Fimmers; Markus Essler; Hojjat Ahmadzadehfar Journal: Clin Cancer Res Date: 2018-06-27 Impact factor: 12.531
Authors: Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree Journal: Histopathology Date: 2019-11-13 Impact factor: 5.087